In studies specifically focused on MS patients, EVOO significantly reduced C-reactive protein (CRP) values, IL-6, IL-7, and IL-18 plasma levels (49), and pro-inflammatory molecule gene expression (50). This evidence concerns the gene IL7 and myeloid sarcoma.